CPT 1550
Alternative Names: CPT-1550Latest Information Update: 28 Jun 2024
At a glance
- Originator Coeptis Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in USA
- 18 May 2021 Coeptis Pharmaceuticals is available for licensing as of 25 May 2021 https://coeptispharma.com/#partnerships (Coeptis Pharmaceuticals website, May 2021)
- 18 May 2021 Clinical trials in Cancer in USA (unspecified route) before May 2021